131 related articles for article (PubMed ID: 34212421)
1. The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways.
Wang L; Chen Y; Li H; Xu Q; Liu R
Fundam Clin Pharmacol; 2022 Feb; 36(1):81-88. PubMed ID: 34212421
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy.
Wei X; Nian J; Zheng J; He Y; Zeng M
Cancer Chemother Pharmacol; 2020 May; 85(5):949-957. PubMed ID: 32279103
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer.
Xi C; Wang L; Yu J; Ye H; Cao L; Gong Z
Biochem Biophys Res Commun; 2019 Jun; 513(3):589-593. PubMed ID: 30979499
[TBL] [Abstract][Full Text] [Related]
4. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Squires MS; Feltell RE; Wallis NG; Lewis EJ; Smith DM; Cross DM; Lyons JF; Thompson NT
Mol Cancer Ther; 2009 Feb; 8(2):324-32. PubMed ID: 19174555
[TBL] [Abstract][Full Text] [Related]
5. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
Santo L; Vallet S; Hideshima T; Cirstea D; Ikeda H; Pozzi S; Patel K; Okawa Y; Gorgun G; Perrone G; Calabrese E; Yule M; Squires M; Ladetto M; Boccadoro M; Richardson PG; Munshi NC; Anderson KC; Raje N
Oncogene; 2010 Apr; 29(16):2325-36. PubMed ID: 20101221
[TBL] [Abstract][Full Text] [Related]
6. Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS‑032, on cervical cancer.
Kang MA; Kim W; Jo HR; Shin YJ; Kim MH; Jeong JH
Int J Oncol; 2018 Aug; 53(2):703-712. PubMed ID: 29901072
[TBL] [Abstract][Full Text] [Related]
7. AT7519 against lung cancer via the IL6/STAT3 signaling pathway.
Zhou F; Zhu F; Zhu T; Zhao Z; Li L; Lin S; Zhao H; Yang L; Zhao C; Wang L; Li J; Huang X
Biochem Biophys Res Commun; 2022 Jun; 609():31-38. PubMed ID: 35413537
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
[TBL] [Abstract][Full Text] [Related]
9. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
10. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
11. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
Squires MS; Cooke L; Lock V; Qi W; Lewis EJ; Thompson NT; Lyons JF; Mahadevan D
Mol Cancer Ther; 2010 Apr; 9(4):920-8. PubMed ID: 20354122
[TBL] [Abstract][Full Text] [Related]
12. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
13. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
[TBL] [Abstract][Full Text] [Related]
14. A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.
Chen EX; Hotte S; Hirte H; Siu LL; Lyons J; Squires M; Lovell S; Turner S; McIntosh L; Seymour L
Br J Cancer; 2014 Dec; 111(12):2262-7. PubMed ID: 25393368
[TBL] [Abstract][Full Text] [Related]
15. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
Joshi KS; Rathos MJ; Mahajan P; Wagh V; Shenoy S; Bhatia D; Chile S; Sivakumar M; Maier A; Fiebig HH; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):926-34. PubMed ID: 17363487
[TBL] [Abstract][Full Text] [Related]
16. Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammation.
Alessandri AL; Duffin R; Leitch AE; Lucas CD; Sheldrake TA; Dorward DA; Hirani N; Pinho V; de Sousa LP; Teixeira MM; Lyons JF; Haslett C; Rossi AG
PLoS One; 2011; 6(9):e25683. PubMed ID: 21984938
[TBL] [Abstract][Full Text] [Related]
17. Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition.
Zhang J; Wang W; Qian L; Zhang Q; Lai D; Qi C
Oncol Rep; 2015 Nov; 34(5):2375-84. PubMed ID: 26323892
[TBL] [Abstract][Full Text] [Related]
18. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
19. RIP1 promotes proliferation through G2/M checkpoint progression and mediates cisplatin-induced apoptosis and necroptosis in human ovarian cancer cells.
Zheng XL; Yang JJ; Wang YY; Li Q; Song YP; Su M; Li JK; Zhang L; Li ZP; Zhou B; Lin Y
Acta Pharmacol Sin; 2020 Sep; 41(9):1223-1233. PubMed ID: 32242118
[TBL] [Abstract][Full Text] [Related]
20. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]